De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care
De novo LTV in R+ KTRs appears to be safe and effective compared to VGC. This study suggests antiviral prophylaxis is more likely to be successfully completed with LTV and requires less dose titration. Additionally, LTV appears to be associated with less myelosuppression, permitting higher mycophenolate doses at 12 months and avoiding corrective healthcare resource utilization.
Authors
- Chris Saddler
- Didier A. Mandelbrot (ORCID: https://orcid.org/0000-0003-3326-8583)
- Jillian L. Descourouez (ORCID: https://orcid.org/0000-0002-1196-5110)
- Michael Scolarici (ORCID: https://orcid.org/0000-0002-3461-310X)
- David Al‐Adra (ORCID: https://orcid.org/0000-0002-4469-6375)
- Margaret R. Jorgenson (ORCID: https://orcid.org/0000-0001-6088-9727)
- Glen Leverson (ORCID: https://orcid.org/0000-0003-2286-3088)
- Hanna L. Kleiboeker (ORCID: https://orcid.org/0000-0003-3149-6558)
Institutions
- University of Wisconsin–Madison (US)
- UW Health University Hospital (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1111/ctr.70423
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00